Ilonze, Onyedika J.Giovannini, MarinaJones, Mark A.Rao, RoopaBallut, KareemGuglin, Maya2021-11-122021-11-122021-10Ilonze, O. J., Giovannini, M., Jones, M. A., Rao, R., Ballut, K., & Guglin, M. (2021). Calcineurin-Inhibitor Induced Pain Syndrome in a Heart Transplant Patient. Transplantation Proceedings, 53(8), 2630-2635. https://doi.org/10.1016/j.transproceed.2021.08.0141873-2623https://hdl.handle.net/1805/26991This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.Calcineurin-inhibitor induced pain syndrome (CIPS) also called the "symmetrical bone syndrome" is a condition describing reversible lower extremity pain in patients after organ transplantation who are receiving calcineurin inhibitors, especially tacrolimus. We present a case of CIPS after orthotopic heart transplant complicated with concurrent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We emphasize the presentation; diagnostic evaluation, and findings. We then discuss the proposed pathophysiologic mechanisms of CIPS and conclude with discussion of management strategies. Additionally, we present a table to guide clinicians in assessing posttransplant bone pain syndromes. To our knowledge, this is the first article to describe a case of CIPS with concurrent SARS-CoV-2 infection.en-USPublic Health EmergencyCalcineurin-InhibitorHeart Transplant Patientorgan transplantationtacrolimusArticle